Glioblastoma: all 1,951 studies

Page 7 of 20. Open to participants first (457), then studies with results posted, then the rest; newest registration first within each.

• Temozolomide 12 Cycles Versus 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma.CompletedNCT02209948Phase 2Results posted
• Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant GliomaActive, not recruitingNCT02208362Phase 1Results posted
• Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade GliomasActive, not recruitingNCT02192359Phase 1Results posted
• Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade GliomasCompletedNCT02186509Phase 1Results posted
• Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed GlioblastomaActive, not recruitingNCT02179086Phase 2Results posted
• 18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent GliomasTerminatedNCT02175745Not applicableResults posted
• Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade GliomaTerminatedNCT02168270Phase 1Results posted
• A Study of Subcutaneous Bevacizumab in Relapsed / Progressive GlioblastomaCompletedNCT02157103Phase 2Results posted
• Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma MultiformeActive, not recruitingNCT02152982Phase 2/3Results posted
• TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid TumorsActive, not recruitingNCT02142803Phase 1Results posted
• Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma MultiformeCompletedNCT02120287Phase 2Results posted
• Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma MultiformeCompletedNCT02078648Phase 1/2Results posted
• FMISO PET Study of GlioblastomaCompletedNCT02076152Not applicableResults posted
• Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive GlioblastomaCompletedNCT02067156Phase 2Results posted
• Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant GliomaActive, not recruitingNCT02062827Phase 1Results posted
• Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive GlioblastomaCompletedNCT02060890Results posted
• Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain TumorsCompletedNCT02052648Phase 1/2Results posted
• Stem Cell Radiotherapy and Temozolomide for Newly Diagnosed High-grade GliomaTerminatedNCT02039778Not applicableResults posted
• A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant GliomaCompletedNCT02026271Phase 1Results posted
• A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma PatientsCompletedNCT02017717Phase 3Results posted
• Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade GliomasCompletedNCT02015819Phase 1Results posted
• Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With GlioblastomaCompletedNCT02014844Phase 2Results posted
• Bevacizumab w / Temozolomide PET & Vascular MRI For GBMCompletedNCT01987830Not applicableResults posted
• Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent GliomasTerminatedNCT01986348Phase 2Results posted
• Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade GliomaCompletedNCT01977677Phase 1/2Results posted
• A Phase 2 Study of BGJ398 in Patients With Recurrent GBMCompletedNCT01975701Phase 2Results posted
• Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior BevacizumabCompletedNCT01931098Phase 2Results posted
• Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344)TerminatedNCT01925573Not applicableResults posted
• Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine GliomasCompletedNCT01922076Phase 1Results posted
• NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent GlioblastomaCompletedNCT01894061Phase 2Results posted
• Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22TerminatedNCT01884740Phase 1/2Results posted
• Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent GlioblastomaTerminatedNCT01870726Phase 1/2Results posted
• BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)CompletedNCT01856933Phase 2Results posted
• Glioblastoma Multiforme (GBM) Proton vs. Intensity Modulated Radiotherapy (IMRT)CompletedNCT01854554Phase 2Results posted
• Tivozanib for Recurrent GlioblastomaCompletedNCT01846871Phase 2Results posted
• Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain TumorsTerminatedNCT01836549Phase 2Results posted
• Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma MultiformeTerminatedNCT01822275Phase 2Results posted
• Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade GliomaCompletedNCT01817751Phase 2Results posted
• Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by SurgeryTerminatedNCT01814813Phase 2Results posted
• Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBMCompletedNCT01811498Phase 1/2Results posted
• 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis TherapyCompletedNCT01806675Phase 1/2Results posted
• A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed GlioblastomaCompletedNCT01790503Phase 1/2Results posted
• TRC105 for Recurrent GlioblastomaTerminatedNCT01778530Phase 2Results posted
• FET-PET for Evaluation of Response of Recurrent GBM to AvastinCompletedNCT01756352Phase 2Results posted
• Calorie-restricted, Ketogenic Diet and Transient Fasting During Reirradiation for Patients With Recurrent GlioblastomaCompletedNCT01754350Not applicableResults posted
• Dovitinib in Treating Patients With Recurrent or Progressive GlioblastomaCompletedNCT01753713Phase 2Results posted
• A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With BevacizumabTerminatedNCT01743950Phase 2Results posted
• Bevacizumab Beyond Progression (BBP)CompletedNCT01740258Phase 2Results posted
• Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma PatientsCompletedNCT01738646Phase 2Results posted
• Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent GlioblastomaCompletedNCT01730950Phase 2Results posted
• Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant AstrocytomasTerminatedNCT01721577Phase 1/2Results posted
• Phase II NKTR-102 In Bevacizumab-Resistant High Grade GliomaCompletedNCT01663012Phase 2Results posted
• Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT01648348Phase 1/2Results posted
• Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial CancerCompletedNCT01631552Phase 1/2Results posted
• Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain TumorsCompletedNCT01609790Phase 2Results posted
• A Study in Recurrent Glioblastoma (GB)CompletedNCT01582269Phase 2Results posted
• Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent GlioblastomaTerminatedNCT01582152Phase 1/2Results posted
• Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma MultiformeTerminatedNCT01575275Phase 2Results posted
• A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With GlioblastomaCompletedNCT01564914Phase 2Results posted
• Imaging Study of Glioblastomas Treated With AvastinTerminatedNCT01549392Not applicableResults posted
• PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404CompletedNCT01540513Not applicableResults posted
• Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.CompletedNCT01520870Phase 2Results posted
• Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine GliomasCompletedNCT01514201Phase 1/2Results posted
• Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) PatientsTerminatedNCT01508117Phase 2Results posted
• PVSRIPO for Recurrent Glioblastoma (GBM)CompletedNCT01491893Phase 1Results posted
• Neural Progenitor Cell Sparing Radiation Therapy Plus TemozolomideCompletedNCT01478854Not applicableResults posted
• Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent GliomasTerminatedNCT01478321Phase 2Results posted
• A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent GlioblastomaCompletedNCT01474239Phase 2Results posted
• Low Dose Radiation Therapy for Glioblastoma MultiformeCompletedNCT01466686Phase 2Results posted
• Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed GlioblastomaCompletedNCT01465347Phase 1/2Results posted
• CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIIICompletedNCT01454596Phase 1/2Results posted
• Phase I-II Everolimus and Sorafenib in Recurrent High-Grade GliomasCompletedNCT01434602Phase 1/2Results posted
• A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)TerminatedNCT01433991Phase 1/2Results posted
• PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT MethylationCompletedNCT01402063Phase 2Results posted
• Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2CompletedNCT01383135Early Phase 1Results posted
• BIBF 1120 for Recurrent High-Grade GliomasCompletedNCT01380782Phase 2Results posted
• Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma MultiformeCompletedNCT01349660Phase 1/2Results posted
• A Phase 2 Study of PLX3397 in Patients With Recurrent GlioblastomaTerminatedNCT01349036Phase 2Results posted
• Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive GlioblastomaCompletedNCT01342757Not applicableResults posted
• Phase II Study of BKM120 for Subjects With Recurrent GlioblastomaCompletedNCT01339052Phase 2Results posted
• Bosutinib in Adult Patients With Recurrent GlioblastomaCompletedNCT01331291Phase 2Results posted
• Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary GlioblastomaCompletedNCT01310868Phase 2Results posted
• Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive GlioblastomaTerminatedNCT01310855Phase 2Results posted
• Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV GliomaCompletedNCT01290692Phase 2Results posted
• Amgen 386 for Recurrent GlioblastomaCompletedNCT01290263Phase 1/2Results posted
• A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)CompletedNCT01280552Phase 2Results posted
• A Study of MEDI-575 in Subjects With Recurrent Glioblastoma MultiformeCompletedNCT01268566Phase 2Results posted
• Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent GlioblastomaCompletedNCT01266031Phase 1/2Results posted
• Memantine for Recurrent GlioblastomaTerminatedNCT01260467Phase 2Results posted
• A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or ProgressionCompletedNCT01259869Phase 2Results posted
• A Study of PD 0332991 in Patients With Recurrent Rb Positive GlioblastomaTerminatedNCT01227434Phase 2Results posted
• Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma MultiformeCompletedNCT01209442Phase 2Results posted
• RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant GliomaTerminatedNCT01189240Phase 1/2Results posted
• Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)TerminatedNCT01186406Phase 2Results posted
• Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple MyelomaCompletedNCT01177397Phase 1/2Results posted
• Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive GlioblastomaTerminatedNCT01122901Phase 2Results posted
• Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma MultiformCompletedNCT01120639Phase 1/2Results posted
• A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma MultiformeCompletedNCT01115491Phase 2Results posted
• TPI 287 in Patients With Recurrent Glioblastoma MultiformeTerminatedNCT01113463Phase 2Results posted
• AMG 102 and Avastin for Recurrent Malignant GliomaCompletedNCT01113398Phase 2Results posted

← Glioblastoma overview